Last updated: February 20, 2026
What is Cresemba?
Cresemba (isbavuconazonium sulfate) is an antifungal drug approved by the U.S. Food and Drug Administration (FDA) in 2015. It treats invasive fungal infections, specifically invasive aspergillosis and mucormycosis. Developed by Pfizer, it belongs broadly to the triazole class, which inhibits fungal cytochrome P450 enzymes.
Market Overview
Clinical Adoption and Market Size
- Target indications: Invasive aspergillosis accounted for approximately 19,000 reported cases globally in 2022, with mucormycosis at roughly 6,000 cases.
- Indications: Limited primarily to immunocompromised patients, including hematology, oncology, and transplant recipients.
- Market penetration: As of 2023, Cresemba's market share among antifungal agents for invasive aspergillosis is estimated at approximately 25-30% in the U.S. and Europe.
-
Competitors:
| Drug |
Approval Year |
Market Share (2023) |
Price (per 200 mg dose) |
Key Points |
| Voriconazole |
2002 |
45% |
$100 |
First-line for aspergillosis |
| Isavuconazole (Cresemba) |
2015 |
25-30% |
$160 |
Broad-spectrum antifungal |
| Posaconazole |
2006 |
15% |
$180 |
Used for prophylaxis |
Key Drivers
- Demographic growth in immunocompromised patient populations.
- The expansion of indications, including mucormycosis.
- Limited oral bioavailability challenges for competitors.
Regulatory Developments
- The FDA approved oral and IV formulations.
- European Medicines Agency (EMA) approval in 2015.
- Ongoing discussions for expanded indications, including invasive fungal infections in pediatric populations.
Distribution and Healthcare Economics
- Primarily dispensed in hospital clinics and specialty pharmacies.
- Price is subject to negotiation, insurance coverage, and institutional formulary decisions.
- Cost-effectiveness studies suggest a higher upfront cost compared to older azoles but lower adverse effects and hospitalization costs offset the price.
Price Projections
Factors Influencing Future Prices
- Competition from generics: No generic versions available yet.
- Cost pressures: Government and insurer efforts to reduce healthcare spending.
- Patent status: Pfizer’s patent protection extends until 2027 in the U.S.
Short-term (2023-2025)
- Price stability expected as patent protection holds.
- Monthly treatment cost: $4,800–$6,400, based on daily doses (200 mg BID for 1-3 months).
- Slight reductions possible through contract negotiations.
Medium to Long-term (2025-2030)
- Patent expiry in 2027 could prompt generic entry.
- Generic introduction likely leads to price reductions of 40-60% over 2-3 years post-patent expiry.
- Slight product improvements or reformulations may temporarily boost prices.
Estimated Price Trends
| Year |
Predicted Price Range (per dose) |
Comments |
| 2023 |
$160 |
Stable, patent protection active |
| 2025 |
$150–$160 |
Slight decline expected |
| 2027 |
$80–$100 (post-generic) |
Patent expiry, price drop |
| 2028–2030 |
$75–$90 |
Generic market saturation |
Revenue Projections
- Global sales exceeded $400 million in 2022.
- Compound annual growth rate (CAGR) from 2023-2025 projected at 4-6%, driven by rising invasive fungal infections.
- Post-2027, sales may decline due to generic competition but remain significant for certain niche indications.
Key Takeaways
- Cresemba is a key player in the invasive fungal infection market, with a leading market share among newer azoles.
- Its pricing remains high due to limited competition and patent protections, with potential significant reductions after patent expiry.
- Market growth hinges on expanded indications and increasing fungal infection prevalence, particularly in aging and immunocompromised populations.
- Price stability expected until 2027, after which generic competition may substantially lower costs.
- Pfizer's ongoing clinical trials and regulatory filings could influence future positioning and pricing.
FAQs
1. When will Cresemba face generic competition?
Patent protection in the U.S. expires in 2027, opening the door for generics and potential price declines.
2. How does Cresemba compare clinically to older azoles?
Cresemba offers a broader spectrum, better safety profile, and fewer drug-drug interactions compared to voriconazole, influencing its adoption in complex cases.
3. What is the reimbursement landscape?
Coverage is negotiated between providers and payers, with high-cost medications often requiring prior authorization and formulary placement.
4. Are there established off-label uses for Cresemba?
Clinical trials are exploring additional indications, but off-label use remains limited and not widely established.
5. How might forthcoming regulatory approvals influence the market?
Expanded indications, such as prophylaxis and pediatric use, could expand its market share and justify premium pricing in new segments.
Sources
[1] U.S. Food and Drug Administration. (2015). Cresemba (isavuconazonium sulfate) approval letter.
[2] IQVIA. (2023). Global antifungal market insights.
[3] Pfizer. (2022). Cresemba prescribing information.
[4] European Medicines Agency. (2015). Cresemba approval decision.
[5] MarketWatch. (2023). Antifungal drugs market analysis.
